Rising Therapy-Related Leukemia Rates Signal New Testing Demands for Clinical Labs

A recent population-based study, published in CANCER, a peer-reviewed journal of the American Cancer Society, has brought into sharp focus a significant and evolving challenge for modern oncology and clinical diagnostics: the rising incidence of therapy-related acute myeloid leukemia (tAML). This secondary blood cancer, a severe consequence linked to prior exposure to chemotherapy and radiation treatments for primary malignancies, is becoming an increasingly visible component of the cancer landscape, demanding a proactive and adaptive response from clinical laboratories worldwide. The study’s findings underscore a critical paradox of medical progress: as advancements in cancer therapies lead to improved survival rates for millions, a subset of these survivors faces new, complex, and often aggressive secondary cancers.

The comprehensive investigation, drawing data from the meticulous records of the Osaka Cancer Registry in Japan, spanning an extensive period from 1990 to 2020, provides compelling evidence of this upward trend. Researchers meticulously analyzed nearly 10,000 cases of acute myeloid leukemia (AML) diagnosed within the registry’s catchment area. Their analysis revealed that 6.5% of all AML cases were classified as therapy-related. More strikingly, the study documented a steady and concerning increase in tAML incidence over the three decades, climbing from 0.13 per 100,000 people in the earlier period to 0.36 per 100,000 people by 2020. This translates to a near doubling of the proportion of tAML within the total AML caseload over the study duration, a clear indicator of a shifting disease burden intrinsically linked to the growing population of cancer survivors.

Dr. Kenji Kishimoto, MD, PhD, the lead author of the study from the Osaka International Cancer Institute, emphasized the significance of these findings, stating, "The study provides an important step towards better understanding how the nature of tAML is changing with the increasing number of cancer survivors." This statement highlights the necessity for ongoing research and a deeper comprehension of the long-term sequelae associated with successful primary cancer treatments. The Osaka Cancer Registry, known for its rigorous data collection and long-term follow-up, offers a robust foundation for such epidemiological analyses, making its insights particularly valuable for global oncology planning.

Understanding Therapy-Related AML: A Consequence of Medical Success

Therapy-related AML is a distinct entity from de novo AML, which arises without prior exposure to cytotoxic treatments. tAML typically emerges months to years after exposure to specific classes of antineoplastic agents, most notably alkylating agents (such as cyclophosphamide, ifosfamide, melphalan, and carmustine) and topoisomerase II inhibitors (like etoposide, doxorubicin, and mitoxantrone), as well as radiation therapy. These treatments, while highly effective in eradicating primary cancer cells, can inadvertently inflict damage on the DNA of hematopoietic stem cells in the bone marrow, leading to clonal evolution and the eventual development of secondary leukemia.

The clinical characteristics of tAML are often more aggressive than de novo AML, frequently presenting with poor-risk cytogenetics, such as monosomy 5 or 7, or complex karyotypes, and specific molecular mutations, including TP53, RUNX1, and PPM1D. These genetic signatures not only distinguish tAML but also contribute to its generally poorer prognosis and resistance to standard AML induction chemotherapy. The median latency period for tAML can vary depending on the type of cytotoxic therapy received; alkylating agent-induced tAML often has a longer latency (5-10 years) and is frequently associated with myelodysplastic syndrome (MDS) features, while topoisomerase II inhibitor-induced tAML typically has a shorter latency (1-3 years) and often presents with balanced translocations.

The Evolution of Cancer Treatment and Survivorship

The rise in tAML incidence is inextricably linked to the remarkable progress made in cancer treatment over the past half-century. In the 1970s, the overall 5-year relative survival rate for all cancers combined in the United States was approximately 50%. By the late 2010s, this figure had climbed to nearly 70%, with even more dramatic improvements seen in specific cancers like breast cancer, prostate cancer, colorectal cancer, and certain childhood leukemias. This improvement is a testament to advances in early detection, surgical techniques, radiation oncology, and, crucially, the development of increasingly potent and sophisticated systemic therapies.

Chemotherapy, introduced as a cornerstone of cancer treatment in the mid-20th century, has continuously evolved, with new agents and combination regimens improving efficacy against a wide spectrum of malignancies. Similarly, radiation therapy has become more precise, minimizing collateral damage while maximizing tumor kill. However, these life-saving interventions come with a spectrum of potential long-term side effects, and tAML represents one of the most severe. The increased use of intensive, multi-agent chemotherapy regimens and higher doses of radiation, particularly for aggressive primary cancers or in younger patients with longer life expectancies, has inadvertently expanded the population at risk for secondary malignancies.

Shifting Patterns in Precursor Cancers

The Osaka study provided valuable insights into the changing landscape of primary cancers preceding tAML diagnoses. Historically, prior hematologic malignancies, such as lymphomas and other leukemias, have been a common precursor to tAML, often due to intensive conditioning regimens involving high-dose chemotherapy and radiation used in stem cell transplantation settings. The study confirmed that prior blood cancers remained the most common precursor category.

However, a significant trend observed was the notable rise in tAML cases following breast cancer treatment. Breast cancer is one of the most prevalent cancers globally, and thanks to advancements in screening and treatment, millions of women are now long-term survivors. The increasing incidence of tAML in this cohort suggests an evolving risk profile potentially linked to the widespread and effective use of anthracyclines (a class of topoisomerase II inhibitors) and alkylating agents in adjuvant and neoadjuvant breast cancer regimens. As treatment protocols adapt and patient populations age, understanding these specific links becomes crucial for risk stratification and tailored follow-up.

Colorectal cancer also represented a notable proportion of precursor cases, reflecting its high incidence and the use of cytotoxic agents in its management. Interestingly, the study observed a decline in gastric cancer-associated tAML cases. This decline could be attributed to several factors, including changes in gastric cancer incidence rates in Japan, which have seen a gradual decrease over decades, as well as potential shifts in treatment protocols for gastric cancer, possibly favoring agents with lower leukemogenic potential or a reduced intensity of treatment in certain patient groups. These specific shifts highlight the dynamic interplay between primary cancer epidemiology, treatment paradigms, and the subsequent risk of secondary cancers.

The Imperative for Clinical Laboratories: Expanding Capabilities

For clinical laboratories, the implications of these findings are profound and necessitate a fundamental recalibration of diagnostic and surveillance strategies. The increasing prevalence of tAML demands an expansion of capabilities across several critical domains:

Enhanced Genomic Testing: The diagnosis and characterization of tAML are increasingly reliant on advanced genomic profiling. Unlike de novo AML, tAML often presents with distinct molecular signatures and complex chromosomal abnormalities. Clinical laboratories must expand their capacity for next-generation sequencing (NGS) panels to identify recurrent mutations (e.g., TP53, RUNX1, PPM1D, ASXL1, SRSF2), as well as conventional cytogenetics and fluorescence in situ hybridization (FISH) for detecting chromosomal aberrations like monosomy 5/7, deletions, and complex karyotypes. These tests are crucial not only for accurate diagnosis but also for prognostication and guiding treatment decisions, as tAML often responds differently to standard therapies.
Robust Surveillance Programs: As more patients become long-term cancer survivors, the need for systematic, longitudinal monitoring for secondary malignancies becomes paramount. Clinical laboratories will play a central role in implementing enhanced surveillance protocols, which may include regular complete blood counts (CBCs) with differential, peripheral blood smear reviews, and, when indicated, bone marrow aspiration and biopsy. Early detection of subtle hematologic changes, even before overt leukemia develops (e.g., myelodysplastic features), could potentially lead to earlier intervention and improved outcomes.
Preparation for Complex Secondary Malignancies: tAML is just one example of a secondary malignancy. Cancer survivors are at risk for a range of secondary cancers, including solid tumors. Laboratories must be equipped to handle the diagnostic challenges of these diverse and often complex cases, requiring a broad repertoire of pathology, immunohistochemistry, and molecular diagnostic tests. The expertise to differentiate a secondary malignancy from a recurrence of the primary cancer, or from a new, unrelated cancer, is critical.
Adaptation of Testing Strategies and Workflows: The influx of tAML cases necessitates a review and adaptation of existing laboratory testing algorithms. This includes optimizing turnaround times for critical genomic tests, ensuring adequate staffing with specialized hematopathologists and molecular pathologists, and integrating bioinformatics tools for the interpretation of complex genomic data. The growing volume and complexity of samples will also drive the need for increased automation and streamlined workflows to maintain efficiency and accuracy.
Interdisciplinary Collaboration: Effective management of tAML and other secondary malignancies requires seamless collaboration between clinical laboratories and oncology, hematology, and radiation oncology teams. Regular communication ensures that laboratory findings are interpreted in the context of a patient’s prior cancer history and treatment regimen, facilitating appropriate clinical management. This collaboration extends to multidisciplinary tumor boards where complex cases are discussed, and diagnostic strategies are refined.

Inferred Statements and Broader Impact

Leading cancer organizations and professional bodies are likely to underscore the importance of these findings. The American Cancer Society, for instance, would likely emphasize the dual challenge of improving cancer survival while mitigating long-term toxicities, advocating for continued research into safer and more targeted therapies. Organizations like the American Association for Clinical Chemistry (AACC) or the College of American Pathologists (CAP) would likely issue guidance to their members, highlighting the need for increased proficiency in tAML diagnostics, investment in genomic technologies, and robust quality assurance programs to ensure accurate and timely results.

From a global perspective, while the Osaka study provides regional data, its implications resonate worldwide. Countries with improving cancer survival rates, particularly those with aging populations and widespread access to modern cancer treatments, are likely to face similar increases in tAML incidence. This calls for international collaboration in data sharing, harmonization of diagnostic criteria, and the development of global guidelines for surveillance and management of long-term cancer survivors. Resource-limited settings, where access to advanced genomic testing may be constrained, face an even greater challenge in accurately diagnosing and managing tAML.

Future Directions and Research Imperatives

The increasing rates of tAML highlight several critical areas for future research and clinical development:

Biomarker Discovery for Risk Stratification: Identifying genetic or molecular biomarkers in primary cancer patients that predict a higher risk of developing tAML could enable personalized treatment approaches, allowing clinicians to select less leukemogenic therapies for at-risk individuals.
Development of Less Genotoxic Therapies: Continued research into novel anti-cancer agents with improved specificity and reduced DNA-damaging potential is crucial. Immunotherapies and targeted therapies, while not entirely without side effects, generally have different toxicity profiles compared to conventional chemotherapy.
Improved Therapeutic Strategies for tAML: Given the aggressive nature and often poorer prognosis of tAML, developing more effective and tailored treatment regimens specifically for this secondary leukemia is an urgent unmet medical need.
Longitudinal Cohort Studies: Establishing large, prospective cohorts of cancer survivors with comprehensive data on their primary cancer treatment and long-term health outcomes will be essential for further elucidating the epidemiology, risk factors, and natural history of tAML.

In conclusion, the findings from the Osaka Cancer Registry serve as a powerful reminder that medical progress often brings new challenges. The increasing rates of therapy-related AML are a direct consequence of improved cancer survival, a triumph of modern medicine. However, this success places a renewed imperative on clinical laboratories to adapt, innovate, and expand their capabilities in genomic testing, surveillance, and interdisciplinary collaboration. By proactively addressing these evolving demands, the healthcare system can ensure that the victories achieved in primary cancer treatment are not overshadowed by the emergence of complex secondary malignancies, ultimately striving for the best possible long-term outcomes for all cancer survivors.